Association between treatment effect on C-peptide preservation and HbA1c in meta-analysis of glutamic acid decarboxylase (GAD)-alum immunotherapy in recent-onset type 1 diabetes

Diabetes Obes Metab. 2022 Aug;24(8):1647-1655. doi: 10.1111/dom.14720. Epub 2022 May 26.

Authors

Christoph Nowak^{1

2}, Ulf Hannelius², Johnny Ludvigsson³

Affiliations

¹ Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Huddinge, Sweden.
² Diamyd Medical AB, Stockholm, Sweden.
³ Crown Princess Victoria Children's Hospital and Division of Pediatrics, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

No abstract available

Keywords: antidiabetic drug; beta cell function; clinical trial; meta-analysis; type 1 diabetes.

Publication types

Meta-Analysis
Research Support, Non-U.S. Gov't

MeSH terms

Alum Compounds
Autoantibodies
C-Peptide
Diabetes Mellitus, Type 1* / drug therapy
Glutamate Decarboxylase*
Glycated Hemoglobin
Humans
Immunologic Factors
Immunotherapy

Substances

Alum Compounds
Autoantibodies
C-Peptide
Glycated Hemoglobin A
Immunologic Factors
aluminum sulfate
Glutamate Decarboxylase